ReviewExpert review of molecular diagnostics2010
Role of somatic mutations in vascular disease formation.
Review in Expert review of molecular diagnostics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- Purification and characterization of an antimicrobial compound against drug-resistant MRSA and VRE produced by Streptomyces levis strain HFM-2.Scientific reports · 2025Article
- Recurrent somatic mutation and progerin expression in early vascular aging of chronic kidney disease.Nature aging · 2025Article
- Updates on the Pathogenesis and Therapeutic Approaches for Hereditary Hemorrhagic Telangiectasia.Current vascular pharmacology · 2025Review
- Genetic variants in patients with multiple arterial aneurysms.Langenbeck's archives of surgery · 2024Article
- Omics Science and Social Aspects in Detecting Biomarkers for Diagnosis, Risk Prediction, and Outcomes of Carotid Stenosis.Biomolecules · 2024Review
- Somatic mutations in single human cardiomyocytes reveal age-associated DNA damage and widespread oxidative genotoxicity.Nature aging · 2022Article
- Marine Anthraquinones: Pharmacological and Toxicological Issues.Marine drugs · 2021Review
- AI (Artificial Intelligence) and Hypertension Research.Current hypertension reports · 2020Review
- Genetics of Arterial-Wall-Specific Mechanisms in Atherosclerosis: Focus on Mitochondrial Mutations.Current atherosclerosis reports · 2020Review
- The Role of Mitochondria in Cardiovascular Diseases.Biology · 2020Review
- Cellular Mechanisms of Human Atherogenesis: Focus on Chronification of Inflammation and Mitochondrial Mutations.Frontiers in pharmacology · 2020Review
- Data on association of mitochondrial heteroplasmy and cardiovascular risk factors: Comparison of samples from Russian and Mexican populations.Data in brief · 2018Article
- An update on clonality: what smooth muscle cell type makes up the atherosclerotic plaque?F1000Research · 2018Review
- Genomic structural variations for cardiovascular and metabolic comorbidity.Scientific reports · 2017Article
- Antimutagenic compounds and their possible mechanisms of action.Journal of applied genetics · 2014Review
- Antigenotoxic effect of lipoic acid against mitomycin-C in human lymphocyte cultures.Cytotechnology · 2013Article
- Molecular studies on coronary artery disease-a review.Indian journal of clinical biochemistry : IJCB · 2013Review
- Prevalence of at-risk genotypes for genotoxic effects decreases with age in a randomly selected population in Flanders: a cross sectional study.Environmental health : a global access science source · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Coronary artery disease, cerebrovascular disease, pulmonary artery hypertension and Alzheimer's disease all lead to substantial morbidity and mortality, and we currently lack effective treatments for these vascular diseases. Since the discovery, decades ago, that atherosclerotic lesions display clonal growth, atherosclerosis and other vascular diseases have been postulated to be neoplastic processes, arising through a series of critical somatic mutations. There is conflicting evidence supporting this but studies of DNA damage and mutagenesis, both genomic and mitochondrial, in atherosclerotic and vascular lesions, have yielded evidence that somatic mutations are involved in atherogenesis and vascular disease development. The roles of mitochondrial DNA damage, oxidative stress and signaling by members of the TGF-beta receptor family are implicated. With the increasing convenience and cost-effectiveness of genome sequencing, it is feasible to continue to seek specific genetic targets in the pathogenesis of these devastating diseases, with the hope of developing personalized genomic medicine in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.